Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$27.95 USD

27.95
503,517

-0.43 (-1.52%)

Updated May 17, 2024 01:11 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.

Why Is Dentsply (XRAY) Up 1% Since Last Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.

What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

DexCom and Papa John's International have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

DexCom and Papa John's International are part of the Zacks Bull and Bear of the Day article.

Urmimala Biswas headshot

3 Stocks From the Growing Digital Orthodontic Space in Focus

by Urmimala Biswas

The orthodontic treatment market has experienced substantial recovery, primarily owing to the easing of restrictions and mass opening up of the economy in 2022.

    The Cooper Companies (COO) Lags Q3 Earnings Estimates

    by Zacks Equity Research

    The Cooper Companies (COO) delivered earnings and revenue surprises of -0.31% and 1.44%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

    DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice

    by Zacks Equity Research

    The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.

    Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    DENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results

    by Zacks Equity Research

    DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.

    AmerisourceBergen (ABC) Q3 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    AmerisourceBergen (ABC) delivered earnings and revenue surprises of 1.95% and 1.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now

    by Zacks Equity Research

    DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

    Is McKesson (MCK) a Great Value Stock Right Now?

    by Zacks Equity Research

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

    Why Is Dentsply (XRAY) Up 6.2% Since Last Earnings Report?

    by Zacks Equity Research

    Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results

    by Zacks Equity Research

    DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.

    SmileDirectClub (SDC) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    SmileDirectClub (SDC) delivered earnings and revenue surprises of -11.76% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.71% and 3.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    New Strong Sell Stocks for May 3rd

    by Zacks Equity Research

    ADT, XRAY, and BGSF have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2022.

    DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

    by Zacks Equity Research

    DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

    Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

    by Zacks Equity Research

    DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.